Cohort study to quantify the risk of glaucoma with intravitreal VEGF inhibitors (bevacizumab, ranibizumab, aflibercept)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/42994
• EU PAS number:
  EUPAS42993
• Study ID:
  42994
• Official title and acronym:
  Cohort study to quantify the risk of glaucoma with intravitreal VEGF inhibitors (bevacizumab, ranibizumab, aflibercept)
• DARWIN EU® study:
  No
• Study countries:
  Canada

  Italy
• Study status:
  Planned

Research institutions and networks

Institutions

University of Siena

University of British Columbia

University of Pisa

University of Firenze Firenze, Azienda Ospedaliera Universitaria Senese Siena, University of British Columbia Vancouver, University of Pisa Pisa

Study timelines

Date when funding contract was signed

Planned: 01/09/2020

Study start date

Planned: 15/09/2021

Date of final study report

Planned: 15/12/2021

Sources of funding

Other

More details on funding

Regional funding (Tuscany region)

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable